Insider Transactions in Q4 2024 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 29
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$68,682
$6.72 P/Share
|
|
Oct 24
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
6,000
-1.14%
|
$36,000
$6.31 P/Share
|
|
Oct 24
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+1.13%
|
$6,000
$1.06 P/Share
|
|
Oct 15
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$68,682
$6.67 P/Share
|
|
Oct 09
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.02%
|
$90,000
$6.36 P/Share
|
|
Oct 09
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.62%
|
$78,750
$2.22 P/Share
|
|
Oct 08
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.04%
|
$90,000
$6.32 P/Share
|
|
Oct 08
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.66%
|
$78,750
$2.22 P/Share
|
|
Oct 03
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$120,000
$6.08 P/Share
|
|
Oct 03
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Oct 02
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$120,000
$6.16 P/Share
|
|
Oct 02
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Oct 01
2024
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,925
+2.48%
|
-
|
|
Oct 01
2024
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,229
+2.06%
|
-
|
|
Oct 01
2024
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,026
+0.03%
|
-
|
|
Oct 01
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$68,682
$6.22 P/Share
|